As the global economy mends, the 2021 growth of Cancer Monoclonal Antibody Partnering Terms and Agreements will have significant change from previous year. According to our (LP Information) latest study, the global Cancer Monoclonal Antibody Partnering Terms and Agreements market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Cancer Monoclonal Antibody Partnering Terms and Agreements market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Cancer Monoclonal Antibody Partnering Terms and Agreements market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Cancer Monoclonal Antibody Partnering Terms and Agreements market, reaching US$ million by the year 2028. As for the Europe Cancer Monoclonal Antibody Partnering Terms and Agreements landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Cancer Monoclonal Antibody Partnering Terms and Agreements players cover 3SBio, 4D Pharma, Abbvie, and Abzena, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Monoclonal Antibody Partnering Terms and Agreements market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
- Asset Purchase
- Collaborative R&D
- Joint Venture
- Licensing
- Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
- Pharmaceutical Industry
- Biotechnology
- Medical Care
- Education and Research
- Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
- 3SBio
- 4D Pharma
- Abbvie
- Abzena
- Adaptive Biotechnologies
- Aeglea BioTherapeutics
- Agenus Bio
- Ascension
- Ascentage Pharma
- Aslan Pharma
- Telix Pharmaceuticals
- Basilea Pharmaceutica
- Bavarian Nordic
- Baxalta
- Bayer
- Cantargia
- Apollomics
- Chiome Bioscience
- Clovis Oncology
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth (Status and Outlook) 2022-2028
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size 2017-2028
2.1.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Segment by Type
2.2.1 Asset Purchase
2.2.2 Collaborative R&D
2.2.3 Joint Venture
2.2.4 Licensing
2.2.5 Other
2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
2.3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2022)
2.4 Cancer Monoclonal Antibody Partnering Terms and Agreements Segment by Application
2.4.1 Pharmaceutical Industry
2.4.2 Biotechnology
2.4.3 Medical Care
2.4.4 Education and Research
2.4.5 Other
2.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
2.5.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2022)
3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Player
3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Players
3.1.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2020-2022)
3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2020-2022)
3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cancer Monoclonal Antibody Partnering Terms and Agreements by Regions
4.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions (2017-2022)
4.2 Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth (2017-2022)
4.3 APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth (2017-2022)
4.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth (2017-2022)
4.5 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth (2017-2022)
5 Americas
5.1 Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022)
5.2 Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
5.3 Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2017-2022)
6.2 APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
6.3 APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements by Country (2017-2022)
7.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements by Region (2017-2022)
8.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
8.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast by Regions (2023-2028)
10.1.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast by Regions (2023-2028)
10.1.2 Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast
10.1.3 APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast
10.1.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast
10.1.5 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast
10.2 Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast by Country (2023-2028)
10.2.1 United States Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.2.2 Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.2.3 Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.2.4 Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.3 APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast by Region (2023-2028)
10.3.1 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.3.2 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.3.3 Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.3.4 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.3.5 India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.3.6 Australia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast by Country (2023-2028)
10.4.1 Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.4.2 France Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.4.3 UK Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.4.4 Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.4.5 Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.5 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast by Region (2023-2028)
10.5.1 Egypt Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.5.2 South Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.5.3 Israel Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.5.4 Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.5.5 GCC Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast
10.6 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast by Type (2023-2028)
10.7 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 3SBio
11.1.1 3SBio Company Information
11.1.2 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 3SBio Main Business Overview
11.1.5 3SBio Latest Developments
11.2 4D Pharma
11.2.1 4D Pharma Company Information
11.2.2 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 4D Pharma Main Business Overview
11.2.5 4D Pharma Latest Developments
11.3 Abbvie
11.3.1 Abbvie Company Information
11.3.2 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Abbvie Main Business Overview
11.3.5 Abbvie Latest Developments
11.4 Abzena
11.4.1 Abzena Company Information
11.4.2 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Abzena Main Business Overview
11.4.5 Abzena Latest Developments
11.5 Adaptive Biotechnologies
11.5.1 Adaptive Biotechnologies Company Information
11.5.2 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Adaptive Biotechnologies Main Business Overview
11.5.5 Adaptive Biotechnologies Latest Developments
11.6 Aeglea BioTherapeutics
11.6.1 Aeglea BioTherapeutics Company Information
11.6.2 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Aeglea BioTherapeutics Main Business Overview
11.6.5 Aeglea BioTherapeutics Latest Developments
11.7 Agenus Bio
11.7.1 Agenus Bio Company Information
11.7.2 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 Agenus Bio Main Business Overview
11.7.5 Agenus Bio Latest Developments
11.8 Ascension
11.8.1 Ascension Company Information
11.8.2 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 Ascension Main Business Overview
11.8.5 Ascension Latest Developments
11.9 Ascentage Pharma
11.9.1 Ascentage Pharma Company Information
11.9.2 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 Ascentage Pharma Main Business Overview
11.9.5 Ascentage Pharma Latest Developments
11.10 Aslan Pharma
11.10.1 Aslan Pharma Company Information
11.10.2 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 Aslan Pharma Main Business Overview
11.10.5 Aslan Pharma Latest Developments
11.11 Telix Pharmaceuticals
11.11.1 Telix Pharmaceuticals Company Information
11.11.2 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.11.4 Telix Pharmaceuticals Main Business Overview
11.11.5 Telix Pharmaceuticals Latest Developments
11.12 Basilea Pharmaceutica
11.12.1 Basilea Pharmaceutica Company Information
11.12.2 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.12.4 Basilea Pharmaceutica Main Business Overview
11.12.5 Basilea Pharmaceutica Latest Developments
11.13 Bavarian Nordic
11.13.1 Bavarian Nordic Company Information
11.13.2 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.13.4 Bavarian Nordic Main Business Overview
11.13.5 Bavarian Nordic Latest Developments
11.14 Baxalta
11.14.1 Baxalta Company Information
11.14.2 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.14.4 Baxalta Main Business Overview
11.14.5 Baxalta Latest Developments
11.15 Bayer
11.15.1 Bayer Company Information
11.15.2 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.15.4 Bayer Main Business Overview
11.15.5 Bayer Latest Developments
11.16 Cantargia
11.16.1 Cantargia Company Information
11.16.2 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.16.4 Cantargia Main Business Overview
11.16.5 Cantargia Latest Developments
11.17 Apollomics
11.17.1 Apollomics Company Information
11.17.2 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.17.4 Apollomics Main Business Overview
11.17.5 Apollomics Latest Developments
11.18 Chiome Bioscience
11.18.1 Chiome Bioscience Company Information
11.18.2 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.18.4 Chiome Bioscience Main Business Overview
11.18.5 Chiome Bioscience Latest Developments
11.19 Clovis Oncology
11.19.1 Clovis Oncology Company Information
11.19.2 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
11.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2020-2022)
11.19.4 Clovis Oncology Main Business Overview
11.19.5 Clovis Oncology Latest Developments
12 Research Findings and Conclusion
List of Tables
Table 1. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Asset Purchase
Table 3. Major Players of Collaborative R&D
Table 4. Major Players of Joint Venture
Table 5. Major Players of Licensing
Table 6. Major Players of Other
Table 7. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & ($ Millions)
Table 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2022)
Table 10. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 11. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & ($ Millions)
Table 12. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2022)
Table 13. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2020-2022) & ($ Millions)
Table 14. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Player (2020-2022)
Table 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Products Offered
Table 16. Cancer Monoclonal Antibody Partnering Terms and Agreements Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions 2017-2022 & ($ Millions)
Table 20. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Regions (2017-2022)
Table 21. Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022) & ($ Millions)
Table 22. Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Country (2017-2022)
Table 23. Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & ($ Millions)
Table 24. Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2022)
Table 25. Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & ($ Millions)
Table 26. Americas Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2022)
Table 27. APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2017-2022) & ($ Millions)
Table 28. APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Region (2017-2022)
Table 29. APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & ($ Millions)
Table 30. APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2022)
Table 31. APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & ($ Millions)
Table 32. APAC Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2022)
Table 33. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022) & ($ Millions)
Table 34. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Country (2017-2022)
Table 35. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & ($ Millions)
Table 36. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2022)
Table 37. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & ($ Millions)
Table 38. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2022)
Table 39. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2017-2022) & ($ Millions)
Table 40. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Region (2017-2022)
Table 41. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & ($ Millions)
Table 42. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2022)
Table 43. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & ($ Millions)
Table 44. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2022)
Table 45. Key Market Drivers & Growth Opportunities of Cancer Monoclonal Antibody Partnering Terms and Agreements
Table 46. Key Market Challenges & Risks of Cancer Monoclonal Antibody Partnering Terms and Agreements
Table 47. Key Industry Trends of Cancer Monoclonal Antibody Partnering Terms and Agreements
Table 48. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 49. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share Forecast by Regions (2023-2028)
Table 50. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 51. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share Forecast by Type (2023-2028)
Table 52. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 53. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share Forecast by Application (2023-2028)
Table 54. 3SBio Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 55. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 56. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 57. 3SBio Main Business
Table 58. 3SBio Latest Developments
Table 59. 4D Pharma Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 60. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 61. 4D Pharma Main Business
Table 62. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 63. 4D Pharma Latest Developments
Table 64. Abbvie Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 65. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 66. Abbvie Main Business
Table 67. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 68. Abbvie Latest Developments
Table 69. Abzena Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 70. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 71. Abzena Main Business
Table 72. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 73. Abzena Latest Developments
Table 74. Adaptive Biotechnologies Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 75. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 76. Adaptive Biotechnologies Main Business
Table 77. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 78. Adaptive Biotechnologies Latest Developments
Table 79. Aeglea BioTherapeutics Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 80. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 81. Aeglea BioTherapeutics Main Business
Table 82. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 83. Aeglea BioTherapeutics Latest Developments
Table 84. Agenus Bio Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 85. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 86. Agenus Bio Main Business
Table 87. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 88. Agenus Bio Latest Developments
Table 89. Ascension Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 90. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 91. Ascension Main Business
Table 92. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 93. Ascension Latest Developments
Table 94. Ascentage Pharma Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 95. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 96. Ascentage Pharma Main Business
Table 97. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 98. Ascentage Pharma Latest Developments
Table 99. Aslan Pharma Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 100. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 101. Aslan Pharma Main Business
Table 102. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 103. Aslan Pharma Latest Developments
Table 104. Telix Pharmaceuticals Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 105. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 106. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 107. Telix Pharmaceuticals Main Business
Table 108. Telix Pharmaceuticals Latest Developments
Table 109. Basilea Pharmaceutica Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 110. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 111. Basilea Pharmaceutica Main Business
Table 112. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 113. Basilea Pharmaceutica Latest Developments
Table 114. Bavarian Nordic Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 115. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 116. Bavarian Nordic Main Business
Table 117. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 118. Bavarian Nordic Latest Developments
Table 119. Baxalta Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 120. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 121. Baxalta Main Business
Table 122. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 123. Baxalta Latest Developments
Table 124. Bayer Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 125. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 126. Bayer Main Business
Table 127. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 128. Bayer Latest Developments
Table 129. Cantargia Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 130. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 131. Cantargia Main Business
Table 132. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 133. Cantargia Latest Developments
Table 134. Apollomics Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 135. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 136. Apollomics Main Business
Table 137. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 138. Apollomics Latest Developments
Table 139. Chiome Bioscience Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 140. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 141. Chiome Bioscience Main Business
Table 142. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 143. Chiome Bioscience Latest Developments
Table 144. Clovis Oncology Details, Company Type, Cancer Monoclonal Antibody Partnering Terms and Agreements Area Served and Its Competitors
Table 145. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offered
Table 146. Clovis Oncology Main Business
Table 147. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 148. Clovis Oncology Latest Developments
List of Figures
Figure 1. Cancer Monoclonal Antibody Partnering Terms and Agreements Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type in 2021
Figure 7. Cancer Monoclonal Antibody Partnering Terms and Agreements in Pharmaceutical Industry
Figure 8. Global Cancer Monoclonal Antibody Partn
Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029
Published: 11-Jan-2024 Price: US 3350 Onwards Pages: 118
The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029.
Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029.
Report Scope
This report aims to provide a comprehensive presentation of the glo......
Global Non-imaging Diagnostic Catheter Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 95
The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
Global Imaging Diagnostic Catheter Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 90
The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......
Global PCR Equipment Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 77
The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030.
PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers:
Advancements in Research and Diagnost......
Global Disposable Sterile Syringes and Needles Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 109
The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030.
North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Disposable Sterile Syringes and N......
Global Orthopaedic Power Tools Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 106
The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030.
North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......
Global Cerebrospinal Fluid Management Devices Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......
Global CAD & CAM Milling Burs Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 79
The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......
Global Artificial Teeth Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 98
The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
